P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

Autor: M. J. van Dijk, M. A. Rab, B. A. van Oirschot, J. Bos, C. Derichs, A. W. Rijneveld, M. H. Cnossen, E. Nur, B. J. Biemond, M. Bartels, J. J. Jans, W. W. van Solinge, R. E. Schutgens, R. van Wijk, E. J. van Beers

Publikováno v: HemaSphere, Vol 6, Pp 1382-1383 (2022)

Externí odkaz: https://doaj.org/article/063dfee7b0054496815fe2b048a8de69

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

Autor: Sjoerd J. F. Hermans, Yvette vanNorden, Jurjen Versluis, Anita W. Rijneveld, Bronno van derHolt, Okke deWeerdt, Bart J. Biemond, Arjan A. van deLoosdrecht, Lotte E. van derWagen, Mar Bellido, Michel vanGelder, Walter J. F. M. van derVelden, Dominik Selleslag, Daniëlle vanLammeren‐Venema, Vincent H. J. van derVelden, Liesbeth C. deWreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Publikováno v: Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)

Abstract Background We recently reported results of the prospective, open‐label HOVON‐100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first‐line treatment with or without clofarabine (CLO). No improvement o

Externí odkaz: https://doaj.org/article/8fb9a56f79554439bf1c21b1d0789f85

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Autor: Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers

Publikováno v: Blood. 140:21-23

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0375de62381a5e7e3d963ea09a28987
https://doi.org/10.1182/blood-2022-155997

Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease:A phase 2, open-label study

Autor: Myrthe J. van Dijk, Minke A. E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J. M. Jans, Wouter W. van Solinge, Roger E. G. Schutgens, Richard van Wijk, Eduard J. van Beers

Publikováno v: van Dijk, M J, Rab, M A E, van Oirschot, B A, Bos, J, Derichs, C, Rijneveld, A W, Cnossen, M H, Nur, E, Biemond, B J, Bartels, M, Jans, J J M, van Solinge, W W, Schutgens, R E G, van Wijk, R & van Beers, E J 2022, ' Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease : A phase 2, open-label study ', American Journal of Hematology, vol. 97, no. 7, pp. E226-E229 . https://doi.org/10.1002/ajh.26554
American Journal of Hematology, 97(7), E226-E229. Wiley-Liss Inc.
American journal of hematology, 97(7), E226-E229. Wiley-Liss Inc.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a7507698a63a3d863b4331778a60cb
https://research.vumc.nl/en/publications/3cbd9677-ca3d-4144-a191-8d69a70eede7

Adolescents and young adults living with an uncertain or poor cancer prognosis

Autor: Olga Husson, Martin G. McCabe, Vivian W G Burgers, Martin J. van den Bent, Daniël J. van der Meer, Anita W. Rijneveld, Winette T. A. van der Graaf

Publikováno v: JNCCN Journal of the National Comprehensive Cancer Network, 19(3), 240-246. Cold Spring Publishing LLC
Burgers, V W G, van der Graaf, W T A, van der Meer, D J, McCabe, M G, Rijneveld, A W, van den Bent, M J & Husson, O 2021, ' Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis : The "New" Lost Tribe ', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 19, no. 3, pp. 240-246 . https://doi.org/10.6004/jnccn.2020.7696

Historically, adolescent and young adult (AYA) patients with cancer, diagnosed for the first time at age 15 through 39 years, have often been identified as a “lost tribe” without a medical “home”; neither pediatric nor adult oncology services

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88352828c30a799da88f81448c9c636d
https://pure.eur.nl/en/publications/11f0561a-a67f-4e72-9654-375d30bd26d2